Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avexis Inc Cmn Stk (AVXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,170,068
  • Shares Outstanding, K 27,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,010 K
  • 36-Month Beta 3.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.93

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.54 +24.63%
on 05/31/17
83.59 -2.28%
on 06/27/17
+6.48 (+8.62%)
since 05/26/17
3-Month
65.23 +25.22%
on 04/11/17
83.59 -2.28%
on 06/27/17
+7.21 (+9.68%)
since 03/28/17
52-Week
31.55 +158.89%
on 08/12/16
85.98 -5.00%
on 03/17/17
+41.28 (+102.18%)
since 06/28/16

Most Recent Stories

More News
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,111,250 shares of its common stock at a price to the public of $70.00 per share before...

AVXS : 81.68 (+4.64%)
AveXis (AVXS) Jumps: Stock Rises 7.1%

AveXis, Inc.(AVXS) was a big mover last session, as the company saw its shares rise over 7% on the day.

REGN : 513.19 (+2.20%)
AVXS : 81.68 (+4.64%)
AveXis Announces Pricing of Public Offering of Common Stock

AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,575,000 shares of its common stock. The net proceeds to AveXis from the offering, after deducting the underwriting...

AVXS : 81.68 (+4.64%)
AveXis (AVXS) Surges: Stock Moves 5% Higher

AveXis (AVXS) was a big mover last session, as the company saw its shares rise over 5% on the day.

VVUS : 1.20 (unch)
AVXS : 81.68 (+4.64%)
AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector

AveXis, Inc. (NASDAQ:AVXS) and REGENXBIO Inc. (NASDAQ:RGNX) today announced an exclusive worldwide license agreement for AveXis to develop and commercialize gene therapy treatments using REGENXBIO's NAV...

RGNX : 20.75 (-0.95%)
AVXS : 81.68 (+4.64%)
What Falling Estimates & Price Mean for AveXis, Inc. (AVXS)

It seems wise to sell the AveXis, Inc. (AVXS) stock at this moment as its both estimates and price have been witnessing downward revision.

AKTX : 5.04 (+0.60%)
AVXS : 81.68 (+4.64%)
AveXis Reports First Quarter 2017 Financial and Operating Results

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results...

AVXS : 81.68 (+4.64%)
AveXis to Report First Quarter 2017 Financial and Operating Results

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will report financial and operating...

AVXS : 81.68 (+4.64%)
AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology

- 10 of 12 patients on proposed therapeutic dose sat unassisted; patient videos demonstrate motor milestone achievement not seen in natural history of disease -

AVXS : 81.68 (+4.64%)
AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology

- Includes Results from Phase 1 Trial of AVXS-101 in SMA Type 1 -

AVXS : 81.68 (+4.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant...

See More

Support & Resistance

2nd Resistance Point 85.02
1st Resistance Point 83.35
Last Price 81.68
1st Support Level 78.66
2nd Support Level 75.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.